Rare case of simultaneous occurrence of chronic neutrophil leukemia and T lymphoblastic lymphoma: case report and literature review

Chronic neutrophil leukemia (CNL) is a rare and life-threatening disease. Cases of CNL combined with lymphoma are rare. Here, we report a case of CNL with T-acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) in a 28-year-old male. After a regimen of ruxolitinib, VICLP (Vincristine, Idarubicin, Cyclop...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2024-10, Vol.103 (10), p.4319-4323
Main Authors: Wang, Shi-xuan, Wang, Fang, Tu, Ye-chao, Zhou, Yu-lan, Tu, Song-tao, Wang, Jie-yu, Lv, Ke-bing, Li, Fei
Format: Article
Language:English
Subjects:
Biopsy
Blood
Blood diseases
Bone marrow
Case Report
Case reports
Chemotherapy
Granulocytes
Hematology
Hyperplasia
Leukemia
Literature reviews
Lymphatic system
Lymphocytes
Lymphoma
Medicine
Medicine & Public Health
Morphology
Mutation
Neutrophils
Oncology
Patients
Remission (Medicine)
Stains & staining
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic neutrophil leukemia (CNL) is a rare and life-threatening disease. Cases of CNL combined with lymphoma are rare. Here, we report a case of CNL with T-acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) in a 28-year-old male. After a regimen of ruxolitinib, VICLP (Vincristine, Idarubicin, Cyclophosphamide, Prednisone, Peg-asparaginase) regimen, high-dose cytarabine, and methotrexate regimens, the patient’s bone marrow condition partially resolved. However, when the disease relapsed four months later, despite attempts with selinexor, venetoclax, and CAG(aclarubicin hydrochloride, Algocytidine, Granulocyte Stimulating Factor) chemotherapy, the leukocytes and peripheral blood primitive cells reduced, but the bone marrow did not achieve remission. This pathogenesis may be related to microenvironmental immune escape under prolonged inflammatory stimulation and gene disruption affecting protein function due to colony-stimulating factor 3 receptor gene (CSF3R) mutations. For this type of disease, early intervention may delay disease progression.
ISSN:0939-5555
1432-0584
1432-0584
DOI:10.1007/s00277-024-05759-z